Evidence map›Paper›PMID 39123199›Full record

ArticleBMC endocrine disorders2024

Association between COVID-19 and the incidence of type 1 diabetes in Portugal - a registry study.

Morten Bjerregaard-Andersen, Jessica Da Silva, Rui Diogo, Ana Raquel Claro, Inês Ferro, Andreia Romana, Patrícia Rocha, Beatriz Sá, Goreti Lobarinhas, Sara Rolim and 21 more

Abstract read
In one paragraph

Article in BMC endocrine disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Morten Bjerregaard-AndersenDepartment of Endocrinology and Nephrology, University Hospital of Southern Denmark, Finsensgade 35, 6700, Esbjerg, Denmark. Morten.Bjerregaard-Andersen2@rsyd.dk.
Jessica Da SilvaInstitute for Interdisciplinary Research, Doctoral Program in Experimental Biology and Biomedicine (PDBEB), University of Coimbra, Coimbra, Portugal.
Rui DiogoHospital Pediátrico de Coimbra, Centro Hospitalar e Universitário de Coimbra (CHUC) E.P.E., Coimbra, Portugal.
Ana Raquel ClaroDepartamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) E.P.E., Lisbon, Portugal.
Inês FerroDepartamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) E.P.E., Lisbon, Portugal.
Andreia RomanaDepartamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) E.P.E., Lisbon, Portugal.
Patrícia RochaCentro Hospitalar de Leiria E.P.E., Leiria, Portugal.
Beatriz SáCentro Hospitalar de Leiria E.P.E., Leiria, Portugal.
Goreti LobarinhasHospital Santa Maria Maior E.P.E., Barcelos, Portugal.
Sara RolimHospital Santa Maria Maior E.P.E., Barcelos, Portugal.
Claus Bogh JuhlDepartment of Endocrinology and Nephrology, University Hospital of Southern Denmark, Finsensgade 35, 6700, Esbjerg, Denmark.
Kurt HøjlundSteno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
Isabel FernandesHospital Espírito Santo E.P.E., Evora, Portugal.
Sónia AntunesHospital Espírito Santo E.P.E., Evora, Portugal.
Maria Manuela Félix CalhaCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Guida GamaCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Sofia AmálioCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Mariana FigueirasCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Teresa SilvaCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Margarida RosadoCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Estela FerrãoCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Luísa ArezCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Ana BaptistaCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Adriana Martins FerreiraCentro Hospitalar do Tâmega e Sousa E.P.E., Guilhufe, Portugal.
Diana AlbaCentro Hospitalar do Tâmega e Sousa E.P.E., Guilhufe, Portugal.
Carlos GodinhoCentro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal.
Ana Luísa LeiteCentro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E) E.P.E., Vila Nova de Gaia, Portugal.
Maria de Lurdes Afonso LopesUnidade de Endocrinologia Pediátrica, Hospital de Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central (CHULC) E.P.E., Lisbon, Portugal.
Maria Lurdes SampaioDepartamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) E.P.E., Lisbon, Portugal.
Joana Serra-CaetanoHospital Pediátrico de Coimbra, Centro Hospitalar e Universitário de Coimbra (CHUC) E.P.E., Coimbra, Portugal.
Eugenia CarvalhoCNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-504, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundViral respiratory infections may precipitate type 1 diabetes (T1D). A possible association between the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, and the incidence of T1D is being determined. This study was carried out using Portuguese registries, aiming at examining temporal trends between COVID-19 and T1D.

methodsHospital data, comparing the incidence before and during the COVID-19 pandemic, from children and young adults diagnosed with new-onset T1D, was acquired beginning in 2017 and until the end of 2022. Data was obtained from nine different Portuguese hospital units. The impact of the COVID-19 pandemic, beginning in March 2020, was assessed comparing the annual numbers of new-onset T1D cases. The annual median levels of glucose, glycated hemoglobin (HbA1c) and fasting C-peptide at T1D diagnosis were compared. The annual number of diabetic ketoacidosis (DKA) episodes among new T1D cases was also assessed at two centers.

resultsIn total, data from 574 newly diagnosed T1D patients was analyzed, including 530 (92.3%) children. The mean ages for child and adult patients were 9.1 (SD 4.4) and 32.8 (SD 13.6) years, respectively. 57.8% (331/573) were male, one patient had unknown sex. The overall median (25-75 percentiles) levels of glucose, HbA1c and fasting C-peptide at diagnosis were 454 mg/dL (356-568), 11.8% (10.1-13.4) and 0.50 µg/L (0.30-0.79), respectively. DKA at T1D diagnosis was present in 48.4% (76/157). For eight centers with complete 2018 to 2021 data (all calendar months), no overall significant increase in T1D cases was observed during the COVID-19 pandemic, i.e. 90 cases in 2018, 90 cases in 2019, 112 in 2020 and 100 in 2021 (P for trend = 0.36). Two of the centers, Faro (CHUA) and Dona Estefânia (CHULC) hospitals, did however see an increase in T1D from 2019 to 2020. No significant changes in glucose (P = 0.32), HbA1c (P = 0.68), fasting C-peptide (P = 0.20) or DKA frequency (P = 0.68) at the time of T1D diagnosis were observed over the entire study period.

conclusionThe T1D incidence did not increase significantly, when comparing the years before and during the COVID-19 pandemic, nor did key metabolic parameters or number of DKA episodes change.

Indexed as

COVID-19Diabetes Mellitus, Type 1RegistriesAdolescentAdultBlood GlucoseChildChild, PreschoolDiabetic KetoacidosisFemaleGlycated HemoglobinHumansIncidenceMalePortugalSARS-CoV-2Blood GlucoseGlycated HemoglobinCOVID-19PortugalType 1 diabetes

Identifiers

PMID39123199
PMCPMC11313027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.